

International Conference on Lung Diseases, October 29-30, 2020 Cape Town, South Africa

Deepika Sharma

Bhutan, E-mail: dsharma@yahoo.com

[Chronic obstructive pulmonary disease](#) (COPD) is the fourth leading causes of death in the world. Moreover, among the top five causes of death, this disease is the only one with increasing mortality rates. COPD is an essential public health problem in many countries which is evaluated to become the fifth reason for disability. COPD is a common condition that mainly affects aged or adults who smoke. The condition cannot be cured or reversed, but for many people treatment can help them to keep it under control so it does not affect their daily activities.

[Respiratory disease](#) affects one in five people in the UK. It is responsible for around a million hospital admissions and costs the NHS an estimated £4.7 billion4 a year. Respiratory disease is also the third biggest cause of death in the UK: in 2012 it killed 80,000 people not including [lung cancer](#), which killed an additional 35,500 people.

The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.

Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the Chronic Obstructive Pulmonary Disease (COPD) market globally. Pharmaceutical companies have been developing new bio-based medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for COPD market over the next decade.

The global COPD drug market is a multi-billion dollar market which has a history of several decades and has witnessed number of technological advancements and product development over the past few years. Upcoming treatment methodologies such as once-a-day combination products and monoclonal antibodies have created new opportunities for the market growth. The global market for [Chronic Obstructive Pulmonary Disease](#) (COPD) prescription drugs was valued at \$34.9 billion in 2011. This figure is expected to reach \$38 billion in 2012 and \$47.1 billion in 2017, growing at a five-year compound annual growth rate (CAGR) of 4.4%. The global COPD market is estimated to currently be worth \$11.3 billion, and is forecast to reach a value of \$15.6 billion by 2019.

Currently, North America leads the global market for [COPD drugs and devices](#). However, North America and Europe is expected to lose out some of the market share to other emerging regional markets owing to the expiry of several patents of pharmaceutical companies operating in these regions. Asia Pacific is estimated to be the rapid regional market for COPD due to the increased incidence of respiratory diseases in industrial regions.





Figure-2

A large decrease in COPD mortality rates COPD deaths fell only slightly, from 3 million in 1990 to 2.8 million in 2010 because the mean age of the population increased. The number of COPD deaths in 2010 would have risen to 5.2 million if the age specific mortality rates had remained constant. Changes in smoking led to only a small increase in age specific mortality rates. Global outlines of mortality are changing, mainly due to three related transformations: an epidemiological transition driven by change in global risks, with falling death rates in childhood associated with [infectious disease](#), a demographic transition with more people surviving into later life, and a health care transition with improved efficacy of both preventive and curative or palliative treatments.

The global [respiratory care](#) devices market was expected to be worth \$8.8 billion in 2010 and is estimated to reach \$13.5 billion by 2015, growing at a CAGR of 8.8% from 2010-2015. The therapeutics devices market dominates the global respiratory care market, followed by monitoring devices and disposables. Within the [therapeutics devices](#) market, positive airway pressure devices account for the largest share and is expected to be \$5.2 billion by the year 2015. The pulse oximeters market dominates the respiratory monitoring devices segment and is expected to reach a market size of \$1.7 billion by the year 2015. Within the respiratory diagnostic devices segment, spirometers dominate the market with an estimated share of \$489 million by 2015.



The emergence of home healthcare has opened new avenues for the respiratory care devices market. Convenience and comfort in a home care environment coupled with cost advantages are the major factors driving the home healthcare market for respiratory care devices.

The U.S. accounts for the largest share of the global respiratory care devices market. Demographic changes and rising incidence of COPD are among the major factors influencing the market. COPD is the fourth leading cause of death in the U.S.; about 12 million Americans suffer from COPD.

The global Respiratory Care market was expected to be worth \$8.8 billion in 2010 and is estimated to reach \$13.5 billion by 2015, growing at a CAGR of 8.8% from 2010-2015. The therapeutics devices market dominates the global Respiratory Care market, followed by monitoring devices and disposables. Within the therapeutics device market, positive airway pressure devices accounts for the largest share and is expected to be \$5.2 billion by the year 2015. The pulse oximeters market dominates the respiratory monitoring devices segment and is expected to reach a market size of \$1.7 billion by the year 2015. Within the respiratory diagnostic devices segment, spirometers dominate the market with an estimated share of \$489 million by 2015.

Dr. Deepika Sharma will be presenting the upcoming event "[International Conference on Lung Diseases](#)" scheduled in October 29-30, 2020 at Cape Town, South Africa.

Contact:
Lavera Valentin
 Program Manager | Lung Diseases 2020
 Mail id: lungdiseases@memeetings.com
 Phone No.: +1-201-380-5561 | Ext. No. 7007
 WhatsApp No.: +44-7723584425